SGLT2 inhibitors and nonsteroidal MRAs represent recent pharmacological advancements alongside traditional RAAS blockers for the treatment of diabetic nephropathy.
What are the emerging pharmacologic treatments for diabetic nephropathy?
SGLT2 inhibitors and nonsteroidal MRAs represent significant recent advancements in the pharmacological management of diabetic nephropathy.
INTRODUCTION: Diabetic nephropathy remains a significant economic and social burden on both the individual patient and health-care systems as the prevalence of diabetes increases in the general population. The complex pathophysiology of diabetic kidney disease poses a challenge in the development of effective medical treatments for the disease. However, the multiple facets of diabetic nephropathy also offer a variety of potential strategies to manage this condition. AREAS COVERED: We retrieved PubMed, Cochrane Library, Scopus, Google Scholar, and ClinicalTrials.gov records to identify studies and articles focused on new pharmacologic advances to treat diabetic nephropathy. EXPERT OPINION: RAAS blockers have remained the mainstay of therapy for DM nephropathy for many years, with only recent advancements with SGLT2 inhibitors and nonsteroidal MRAs. Better understanding of the long-term renal effects of ambient hyperglycemia, ranging from hemodynamic changes to increased production of oxidative and pro-inflammatory substances, has evolved our approach to the treatment of diabetic nephropathy. With continuing research for new therapeutics as well as combination therapy, the medical community may be able to better ease the burden of diabetic kidney disease.
Kim et al. (Sun,) conducted a review in Diabetic nephropathy. SGLT2 inhibitors and nonsteroidal MRAs was evaluated. SGLT2 inhibitors and nonsteroidal MRAs represent recent pharmacological advancements alongside traditional RAAS blockers for the treatment of diabetic nephropathy.